AIC	Akaike information criterion
AJCC	American Joint Committee on Cancer
AUC	area under the curve
BCSS	bladder cancer-specific survival
CI	confidence interval
cTNM	clinical tumor–node–metastasis stage
CT	computed tomography
dd-MVAC	dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin
EFS	event-free survival
HR	hazard ratio
IQR	interquartile range
LVI	lymphovascular invasion
MIBC	muscle-invasive bladder cancer
NAC	neoadjuvant chemotherapy
NLR	neutrophil-to-lymphocyte ratio
NMIBC	non–muscle-invasive bladder cancer
NR	not reached
OS	overall survival
pCR	pathological complete response
pTNM	pathological tumor–node–metastasis stage
RC	radical cystectomy
ROC	receiver operating characteristic
TUR	transurethral resection of bladder tumor
TTNAC	time from transurethral resection to neoadjuvant chemotherapy initiation
ypTNM	post-neoadjuvant pathological tumor–node–metastasis stage